UK biotechnology company developing small-molecule cancer immunotherapies that transiently inhibit DNA mismatch repair (MMR), inducing neoantigen creation and aiming to make tumors more responsive to immune checkpoint blockade
UK biotechnology company developing small-molecule cancer immunotherapies that transiently inhibit DNA mismatch repair (MMR), inducing neoantigen creation and aiming to make tumors more responsive to immune checkpoint blockade. Its pipeline includes PMS2 and MLH1 programmes.